Search

Delamanid

response to standardized antituberculosis treatments as [DB00951] and [DB01045]. … Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).

Rubidium

Resorcinol

It is used as an antiseptic and disinfectant in topical pharmaceutical products in the treatment of skin disorders and infections such as acne, seborrheic dermatitis, eczema, psoriasis, corns, calluses … Although it is primarily indicated for use as a topical application, resorcinol also possesses a well-documented anti-thyroidal activity that is generally not relied upon for any kind of formal therapeutic

Thiosulfuric acid

[A252827] Sodium thiosulfate is rapidly degraded in the stomach; therefore, it is normally administered through other routes, such as intravenous or topical.

Secukinumab

Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque … [A249805] It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.

Technetium Tc-99m disofenin

for liver uptake) as are other tracers from the iminodiacetic acid. … It is available as an intravenous injection in a preparation kit under the name Hepatolite.

Irbesartan

[L7456,L7459] It can also be used as part of a combination product with [hydrochlorothiazide] for patients not well controlled or not expected to be well controlled on monotherapy.

Ethylenediamine

It is also used as an excipient in many pharmacological preparations such as creams. Notably, ethylenediamine is a contact sensitizer capable of producing local and generalized reactions [A34285]. … Ethylenediamine is an organic compound that is used as a building block for the production of many other chemical products.

Reslizumab

Approved by the FDA in March 2016, reslizumab is marketed under the brand name Cinqair for intravenous injection. It is injected once every four weeks via intravenous infusion. … Reslizumab is marketed as Cinqaero in Europe.

Pancuronium

As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.